Pharmaceutical

Novartis eyes $2.9bn MorphoSys buyout to expand oncology pipeline

Pending a successful acquisition, Novartis will obtain pelabresib for myelofibrosis and tulmimetostat for solid tumours or lymphomas.

Feb 6, 2024 - 18:00
Novartis eyes $2.9bn MorphoSys buyout to expand oncology pipeline
Pending a successful acquisition, Novartis will obtain pelabresib for myelofibrosis and tulmimetostat for solid tumours or lymphomas.
Read the original article

Tags:

Previous Article

Rani reports positive data for non-injectable Stelara biosimilar

Next Article

Alternative therapies are needed to combat the impending threat of AMR

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Opaque conflicts permeate prescription drug benefits; Sanofi prevails in Zantac arbitration

STAT+: Pharmalittle: Opaque conflicts permeate prescrip...

Jun 20, 2023

Colombia’s president signs law to strengthen pharmaceutical sector

Colombia’s president signs law to strengthen pharmaceut...

Aug 21, 2024

STAT+: What to know about this year’s Medicare open enrollment period

STAT+: What to know about this year’s Medicare open enr...

Oct 16, 2023